Browsing Centre for Biochemical Pharmacology by Author "Garcia Gil, E"
Now showing items 1-3 of 3
-
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison, TW; Chanez, P; Menzella, F; Canonica, GW; Louis, R; Cosio, BG; Lugogo, NL; Mohan, A; Burden, A; McDermott, L (Elsevier, 2020-12-22)BACKGROUND: ANDHI was done to assess the efficacy of benralizumab, including onset of effect and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and nasal polyposis symptoms. METHODS: ... -
Reply to "Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry".
Chen, W; Tran, TN; Sadatsafavi, M; Murray, RB; Boon Wong, NC; Ali, N; Ariti, C; Bulathsinhala, L; Garcia Gil, E; FitzGerald, JM (2024-02) -
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy.
Louis, R; Harrison, TW; Chanez, P; Menzella, F; Philteos, G; Cosio, BG; Lugogo, NL; de Luiz, G; Burden, A; Adlington, T (2023-06)BACKGROUND: The phase IIIb, randomized, parallel-group, placebo-controlled ANDHI double-blind (DB) study extended understanding of the efficacy of benralizumab for patients with severe eosinophilic asthma. Patients from ...